Russell Investments Core Plus Bond ETF(BD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BD Russell Investments Core Plus Bond ETF

未开盘 09-30 16:00:00 EDT

23.85

-0.04

-0.15%

盘后23.89

+0.04+0.15%

16:04 EDT

最高23.85	最低23.85	成交量21.00
今开23.89	昨收23.89	日振幅0.00%
总市值5,592万	流通市值5,592万	总股本234.50万
成交额506.00	换手率0.00%	流通股本234.50万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BD","market":"US","secType":"STK","nameCN":"Russell Investments Core Plus Bond ETF","latestPrice":23.8481,"timestamp":1790798400000,"preClose":23.885,"halted":0,"volume":21,"hourTrading":{"tag":"盘后","latestPrice":23.885,"preClose":23.8481,"latestTime":"16:04 EDT","volume":4,"amount":95.3924,"timestamp":1790798644529,"change":0.0369,"changeRate":0.001547,"amplitude":0},"delay":0,"changeRate":-0.0015449026585724437,"floatShares":2345000,"shares":2345000,"eps":0,"marketStatus":"未开盘","change":-0.0369,"latestTime":"09-30 16:00:00 EDT","open":23.885,"high":23.8481,"low":23.8481,"amount":506,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":23.885,"nav":23.943272,"aum":56146973.87,"dividendRate":0.009414,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.885,"preClose":23.8481,"latestTime":"16:04 EDT","volume":4,"amount":95.3924,"timestamp":1790798644529,"change":0.0369,"changeRate":0.001547,"amplitude":0},"volumeRatio":0.011038},"requestUrl":"/m/hq/s/BD","defaultTab":"news","newsList":[{"id":"2668911161","title":"【中经社信号】减重药市场需求大 国产药向差异化要空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2668911161","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668911161?lang=zh_cn&edition=full","pubTime":"2026-09-18 10:45","pubTimestamp":1789699524,"startTime":"0","endTime":"0","summary":"近期，多家涉足减重赛道的上市公司交出亮眼“成绩单”。如信达生物2026年上半年净利润已超2025年全年，甘李药业自主研发长效GLP-1受体激动剂双周制剂博凡格鲁肽斩获约56亿元对外授权（BD）大单。但跨国制药巨头礼来、诺和诺德的替尔泊肽、司美格鲁肽两款明星产品，2026年上半年合计销售超450亿美元，继续占据着全球减重市场绝大部分市场份额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878406919.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878406919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","JDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667620418","title":"企业“出海”进阶 从产品输出迈向能力输出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667620418","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667620418?lang=zh_cn&edition=full","pubTime":"2026-09-16 06:58","pubTimestamp":1789513080,"startTime":"0","endTime":"0","summary":"苏州纳微科技股份有限公司董事长江必旺在回答《证券日报》记者提问时说，中国药企的海外授权合作交易爆发，不仅涉及早期项目，更覆盖技术平台、临床开发及商业化全链条，这标志着中国药企从“产品输出”向“能力输出”的跃迁。除了“出海”之外，立足自身主营业务并推进产品多元化升级，蓄力夯实企业长期发展根基也是上市公司的共识。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-16/doc-inirykpk3177466.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-16/doc-inirykpk3177466.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320971","title":"480家药企，最新营收、净利润来了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320971","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665320971?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:39","pubTimestamp":1788867540,"startTime":"0","endTime":"0","summary":"2026年上半年，480家药企合计实现营收7,369.82亿元，同比增长+2.48%；实现归母净利润988.94亿元，同比增长+12.35%。荣昌生物营收58.53亿元，归母净利润46.62亿元，主要受海外授权合作首付款及里程碑款驱动，是板块利润暴增的最大来源。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-08/doc-inircmeq9268445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773564","title":"港股异动 | 乐普生物(02157)午后涨超5% 上半年收入同比增长12.1% 即将跑通CMG901的BD全链条","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773564","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662773564?lang=zh_cn&edition=full","pubTime":"2026-08-27 13:54","pubTimestamp":1787810081,"startTime":"0","endTime":"0","summary":"消息面上，近日，乐普生物发布截至2026年6月30日止六个月业绩，收入5.22亿元，同比增长12.1%；公司拥有人应占利润2739.3万元，同比下降34.4%；每股基本盈利0.02元。国联民生证券发布研报称，乐普生物CMG901全球权益授权阿斯利康、MRG007大中华区外权益授权ArriVent，实现研发能力变现。在商业模式上，公司已成功构建并验证了国内商业化能力，同时即将跑通CMG901的BD全链条。这标志乐普生物能够通过国内商业化和海外授权双轮驱动，持续优化收入结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","VXUS","BK4588","BD","KCAI","02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662623760","title":"【券商聚焦】国投证券维持康诺亚-B（02162）买入评级 指核心产品放量及BD兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2662623760","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662623760?lang=zh_cn&edition=full","pubTime":"2026-08-26 14:06","pubTimestamp":1787724376,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券发布研报指，康诺亚-B 2026年中期实现营业收入6.17亿元人民币，同比增长24%；实现净利润12.18亿元人民币，上年同期为亏损0.79亿元。收入及利润变化主要受核心产品康悦达销售放量及海外BD里程碑收入确认影响。截至2026年6月30日，公司现金及金融资产合计32.42亿元人民币，较年初增长65%。考虑到康悦达医保放量、海外BD授权持续兑现及CM512等管线临床进展，维持“买入-A”评级，根据DCF模型给予6个月目标价90.37港元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YzM1MzBiNWM5MmUxNDYxMGFiODk0MWI5MWJmNTU3YjMxMTA4MTkwNzI1ODY3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989484","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","02162","KCE","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662994764","title":"信达生物：对2030年总收入预期较为保守 BD首付款将有效覆盖研发投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2662994764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662994764?lang=zh_cn&edition=full","pubTime":"2026-08-26 11:58","pubTimestamp":1787716704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662476198","title":"直击业绩会｜加科思首次实现盈利，董事长王印祥：希望通过BD在全球收获回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2662476198","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662476198?lang=zh_cn&edition=full","pubTime":"2026-08-26 10:45","pubTimestamp":1787712326,"startTime":"0","endTime":"0","summary":"8月25日盘后，加科思（HK01167，股价6.000港元，市值46.93亿港元）在线上召开2026年中期业绩投资者电话会。前一晚，公司发布2026年半年报，上半年实现营业收入7.31亿元，同比增加1499.30%；实现归母净利润6.01亿元，较上年同期的-5900万元实现扭亏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854332732.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854332732.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738086","title":"诺诚健华上半年扭亏为盈，高管强调BD会审慎筛选合作方","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738086","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738086?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:49","pubTimestamp":1787651340,"startTime":"0","endTime":"0","summary":"“公司收入来自商业化销售叠加BD双驱动，公司对2026年持续盈利充满信心，BD（业务拓展）交易谈判会审慎筛选优质合作方。”在8月25日的2026上半年业绩说明会上，诺诚健华（9969.HK；688428.SH）联合创始人、董事长兼首席执行官崔霁松表达了上述观点。诺诚健华成立于2015年，2020年在港交所上市，2022年登陆科创板，2025年公司首次实现年度盈利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608253852971124.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608253852971124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","BK1161","688428","BK1574","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660477171","title":"港股异动 | 先声药业(02096)早盘涨超5% 今日将发中期业绩 创新药及BD收入带动业绩高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477171","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660477171?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:32","pubTimestamp":1787193141,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业早盘涨超5%，截至发稿，涨4.27%，报12.69港元，成交额4017.4万港元。消息面上，先声药业将于8月21日召开2026年中期业绩发布会。主要归因于创新药收入和对外授权许可收入的增加。预计公司全年内生业务维持中报预告趋势，同时利润端受益BD继续跨越式提升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LNGR","BK4585","KCAI","BD","BK1161","BK4588","IBBQ","02096","BK1583","MEDX","BK1574","VXUS","159992","BK1191","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660448051","title":"【券商聚焦】国盛证券首予石药集团（01093）买入评级 指其创新转型与BD出海双轮驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448051","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660448051?lang=zh_cn&edition=full","pubTime":"2026-08-19 15:44","pubTimestamp":1787125471,"startTime":"0","endTime":"0","summary":"国盛证券指出，公司构建“自研管线+BD出海”双轮驱动创新研发体系。通过可比公司估值法，给予公司2027年23倍PE，对应目标价13.41港元，首次覆盖给予“买入”评级。报告同时提示研发失败、产品商业化不及预期、BD里程碑收入确认节奏不确定、集采政策持续影响、估值与盈利预测假设及专利知识产权等风险。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988694","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","BD","KCE","002670"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659421174","title":"海外BD大单落定，国产胰岛素龙头借力减重药能否开启新增长曲线？","url":"https://stock-news.laohu8.com/highlight/detail?id=2659421174","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659421174?lang=zh_cn&edition=full","pubTime":"2026-08-16 17:05","pubTimestamp":1786871100,"startTime":"0","endTime":"0","summary":"海归博士创立的胰岛素龙头，净利润难复巅峰在凭借博凡格鲁肽获得市场高度关注之前，甘李药业最为人熟知的身份是国产胰岛素龙头。在国内三代胰岛素市场上，除诺和诺德、赛诺菲、礼来三大外企外，甘李药业市场份额最高，是国产三代胰岛素龙头。拿下海外授权许可大单，甘李药业能否迎来爆发？此次与美纳里尼的授权金额，也创出了博凡格鲁肽授权金额新高。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-08-16/doc-ininnzcn1015795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659317314","title":"全球客户“反向出差”到中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2659317314","media":"央视财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659317314?lang=zh_cn&edition=full","pubTime":"2026-08-15 22:18","pubTimestamp":1786803480,"startTime":"0","endTime":"0","summary":"在央视财经《对话》节目中，主持人陈伟鸿与几位中国科技企业的创始人聊起了一个有趣的变化：过去，中国企业出海往往意味着带着样品和销售团队满世界飞；而现在，一种相反的场景正在频繁出现——海外客户主动来中国“出差”。数据正在印证这一趋势：5月落幕的杭州第二届国际人形机器人展，累计达成合作签约56项、合作意向237项，总金额超213亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608153842453753.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608153842453753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","ROBO","KOMP","ARTY","PBOT","AIPO","BD","QTOC","CHAT","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152904","title":"别慌！机构资金都流向了这里！","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152904","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659152904?lang=zh_cn&edition=full","pubTime":"2026-08-13 20:23","pubTimestamp":1786623796,"startTime":"0","endTime":"0","summary":"今天（8月13日），A股早盘三大指数集体高开，CPO等板块全线走强，“易中天”强势上涨，封板个股比比皆是。然而，下午2点左右，画风突变，上午追高的资金，午后被悉数套牢，截至收盘，仅创新药一枝独秀。那么，科技冲高回落，医药逆势爆发，这究竟发生了什么？今天这篇文章，笔者将逐一拆解。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133840675371.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133840675371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02846","OCS","LU2328871848.SGD","BK1500","BK1574","KURE","LU1969619763.USD","IBBQ","BK1583","LU0228659784.USD","LU0588546209.SGD","83130","BK1161","BK4007","LU0307460666.USD","LU1251922891.USD","82846","LU0828237510.HKD","CPI","399300","07233","83188","BD","BK1588","LNGR","BK1147","02827","03130","06160","159982","03188","LU1303224171.USD","LU1719994722.HKD","MEDX","LU1770034418.SGD","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186026","title":"从“抢BD”到重现金流 创新药产业投资逻辑生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186026","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659186026?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:26","pubTimestamp":1786577165,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BD","MEDX","SPHQ","159399","BK4588","LNGR","BK1574","IBBQ","BK1161","BK4585","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659186206","title":"从“抢BD”到重现金流 创新药产业投资逻辑生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2659186206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659186206?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:15","pubTimestamp":1786576513,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","BK4585","BK4588","IBBQ","BD","SPHQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK1500","IE0009355771.USD","PTH","LU0889565916.HKD","BK1574","BK1588","IDNA","BK4139","IE0009354923.USD","IE00BFTCPJ56.SGD","KURE","BD","RVMD","CANC","LU1969619763.USD","BBH","LU2328871848.SGD","LU0307460666.USD","LU1719994722.HKD","06160","603087","LU1770034418.SGD","09939","LU1251922891.USD","LU0828237510.HKD","688235","IE0002141913.USD","LU0228659784.USD","IE00BJJMRZ35.SGD","BK4588","IE00BJT1NW94.SGD","LU1303224171.USD","BK4526","LU0109394709.USD","BK1161","ONC","BK4585","LU0588546209.SGD","BK1515","BK1583","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658986658","title":"从BD高光到亏损回归，百利天恒面临什么考题？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658986658","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658986658?lang=zh_cn&edition=full","pubTime":"2026-08-10 15:49","pubTimestamp":1786348144,"startTime":"0","endTime":"0","summary":"相对于坎坷的赴港闯关之路，在生物科技这条赛道上，百利天恒已有产品实现商业化。从项目成熟度看，百利天恒并非停留在“早期研发概念验证”阶段。盈利高峰来自授权兑现，亏损继续扩大百利天恒最容易抓住眼球的，是其利润表在近两年出现过明显波动。这组数据本身已经足够说明，百利天恒并不是一家已经进入稳定盈利通道的创新药企业。从这个角度看，百利天恒的长板与短板都很鲜明。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786328428501757201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","688506","BD","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658792716","title":"BD交易破千亿美元 中国创新药距离“全球大单品”还有多远？","url":"https://stock-news.laohu8.com/highlight/detail?id=2658792716","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658792716?lang=zh_cn&edition=full","pubTime":"2026-08-09 12:36","pubTimestamp":1786250165,"startTime":"0","endTime":"0","summary":"8月5日，上海。2026沙利文峰会生命科学新投资高峰论坛上，一组数据让在场者屏息：2026年上半年，中国创新药对外授权（License-out）交易潜在总额达1100亿美元，交易规模达到2025年全年的八成。全球Top10BD交易中，中国独占8席。八年前，当港交所18A章刚刚落地时，中国创新药企还在用“烧十年钱、做研发、等审批”的循环艰难求生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835903315.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835903315.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","BD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656374770","title":"“新新三样”之中国创新药：千亿级BD背后的体系突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2656374770","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656374770?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:33","pubTimestamp":1785763991,"startTime":"0","endTime":"0","summary":"今年以来，中国制造出海出现了越来越多新面孔。前两年，电动载人汽车、锂电池、太阳能电池被称为出口“新三样”，而今年上半年，机器人、人工智能、创新药成为未来产业方向的“新新三样”。数据显示，中国创新药企2026年上半年的海外授权（BD）交易总额，逼近2025年全年1357亿美元的七成，较2024年更是近乎翻倍。然而，比这一惊人数字更值得关注的，是交易结构的深层质变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608033830056118.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608033830056118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656322031","title":"【券商聚焦】华泰证券维持先声药业（02096）买入评级 指新品放量及BD常态化","url":"https://stock-news.laohu8.com/highlight/detail?id=2656322031","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656322031?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:18","pubTimestamp":1785748719,"startTime":"0","endTime":"0","summary":"在行业波动背景下，公司超预期的业绩表现展现了新品种的强烈市场需求及高管变动后的效率提升，同时BD的常态化有望带来持续新增量。预计全年内生业务维持中报预告趋势，利润端受益于BD将继续跨越式提升。此外，在SIM0709年初实现BD及SIM0500后续潜在里程碑等带动下，预计公司合作收入将步入常态化，带来持续的收入增量。TCE平台SIM0500的I期数据有望年内读出，TOPOi毒素ADC平台已通过SIM0613和SIM0505的BD出海得到全面验证。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987337","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BD","02096"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":-0.0366},{"period":"3month","weight":-0.0491},{"period":"6month","weight":-0.0491},{"period":"ytd","weight":-0.0491}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"ARCA","name":"Russell Investments Core Plus Bond ETF","nameEN":"Russell Investments Core Plus Bond ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Russell Investments Core Plus Bond ETF(BD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Russell Investments Core Plus Bond ETF(BD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Russell Investments Core Plus Bond ETF,BD,Russell Investments Core Plus Bond ETF股票,Russell Investments Core Plus Bond ETF股票老虎,Russell Investments Core Plus Bond ETF股票老虎国际,Russell Investments Core Plus Bond ETF行情,Russell Investments Core Plus Bond ETF股票行情,Russell Investments Core Plus Bond ETF股价,Russell Investments Core Plus Bond ETF股市,Russell Investments Core Plus Bond ETF股票价格,Russell Investments Core Plus Bond ETF股票交易,Russell Investments Core Plus Bond ETF股票购买,Russell Investments Core Plus Bond ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Russell Investments Core Plus Bond ETF(BD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Russell Investments Core Plus Bond ETF(BD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}